Skip to content
PLRXPliant Therapeutics, Inc.

Earnings

When Pliant Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

31 quarters. Mar 31, 2019 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 10, after the close

Wed, Mar 10, 2027in 112 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 26 – Mar 12

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2024 n/m, Q3 2024 n/m, Q2 2024 −100.0%, Q1 2024 −100.0%
Net income
-$23.58M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2024 · derived$0.00No Q4 2023 on file

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$24.38M
    N/M
    EPS
    -$0.39
    N/M
    Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported third quarter 2026 financial results.
  2. Q2 2026Aug 11, 2026, after the closeThe release+3.9%by the close of Aug 12
    Revenue
    —
    —
    Net income
    -$22.37M
    N/M
    EPS
    -$0.36
    N/M
  3. Q1 2026May 11, 2026, after the closeThe release1.7%by the close of May 12
    Revenue
    —
    —
    Net income
    -$20.04M
    N/M
    EPS
    -$0.32
    N/M
  4. Q4 2025Mar 11, 2026, after the closeThe release+5.6%by the close of Mar 12
    Revenue
    —
    —
    Net income
    -$23.58M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q——-$0.39—
Q2 2026Jun 30, 2026Aug 11, 2026 · after-hoursAug 11, 202642 d10-Q——-$0.36+3.9%
Q1 2026Mar 31, 2026May 11, 2026 · after-hoursMay 11, 202641 d10-Q——-$0.321.7%
FY 2025
Q4 2025derivedDec 31, 2025Mar 11, 2026 · after-hoursMar 11, 202670 d10-K———+5.6%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q——-$0.43+3.9%
Q2 2025Jun 30, 2025—Aug 7, 202538 d10-Q——-$0.711.8%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 8, 202538 d10-Q——-$0.923.4%
FY 2024
Q4 2024derivedDec 31, 2024Mar 3, 2025 · after-hoursMar 3, 202562 d10-K$0.00——2.2%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$0.00—-$0.951.4%
Q2 2024Jun 30, 2024Aug 7, 2024 · after-hoursAug 7, 202438 d10-Q$0.00−100.0%-$0.92—
Q1 2024Mar 31, 2024May 6, 2024 · after-hoursMay 6, 202436 d10-Q$0.00−100.0%-$0.781.2%
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026000125
10-QAug 11, 2026000113
10-QMay 11, 2026000090
10-KMar 11, 2026000037
10-QNov 6, 2025000175
10-QAug 7, 2025000150
10-QMay 8, 2025000099
10-KMar 3, 2025000054
10-QNov 7, 2024000171
10-QAug 7, 2024000145

Provenance

ProvenanceData status and checks

Pliant Therapeutics, Inc. · CIK 1746473 · Engraved from SEC EDGAR